WHO Expert Committee on Leprosy
Encyclopedia
WHO Expert Committee on Leprosy is constituted by World Health Organization
to study the worldwide progress of Leprosy
.
World Health Organization
The World Health Organization is a specialized agency of the United Nations that acts as a coordinating authority on international public health. Established on 7 April 1948, with headquarters in Geneva, Switzerland, the agency inherited the mandate and resources of its predecessor, the Health...
to study the worldwide progress of Leprosy
Leprosy
Leprosy or Hansen's disease is a chronic disease caused by the bacteria Mycobacterium leprae and Mycobacterium lepromatosis. Named after physician Gerhard Armauer Hansen, leprosy is primarily a granulomatous disease of the peripheral nerves and mucosa of the upper respiratory tract; skin lesions...
.
Reports
- First report published as Technical Report Series No. 71 in 1954.
- Second report published as Technical Report Series No. 189 in 1960.
- Third report published as Technical Report Series No. 319 in 1966.
- Fourth report published as Technical Report Series No. 459 in 1970.
- Fifth report published as Technical Report Series No. 607 in 1977.
- Sixth report published as Technical Report Series No. 768 in 1988.
- Seventh report published as Technical Report Series No. 874 in 1998. They concluded that a single dose of a combination of rifampicinRifampicinRifampicin or rifampin is a bactericidal antibiotic drug of the rifamycin group. It is a semisynthetic compound derived from Amycolatopsis rifamycinica ...
, ofloxacinOfloxacinOfloxacin is a synthetic chemotherapeutic antibiotic of the fluoroquinolone drug class considered to be a second-generation fluoroquinolone. The original brand, Floxin, has been discontinued by the manufacturer in the United States on 18 June 2009, though generic equivalents continue to be...
and minocyclineMinocyclineMinocycline is a broad-spectrum tetracycline antibiotic, and has a broader spectrum than the other members of the group. It is a bacteriostatic antibiotic, classified as a long-acting type...
is an acceptable and cost-effective alternative regimen for the treatment of single-lesion paucibacillary leprosy and the duration of the standard regimen for multibacillary leprosy could be shortened to 12 months.